470 related articles for article (PubMed ID: 27009962)
1. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
[TBL] [Abstract][Full Text] [Related]
2. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
3. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.
McGinnes Cullen L; Schmidt MR; Kenward SA; Woodland RT; Morrison TG
J Virol; 2015 Jul; 89(13):6835-47. PubMed ID: 25903340
[TBL] [Abstract][Full Text] [Related]
4. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
6. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
McGinnes Cullen L; Schmidt MR; Morrison TG
J Virol; 2019 May; 93(9):. PubMed ID: 30760576
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
[TBL] [Abstract][Full Text] [Related]
8. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
9. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
[TBL] [Abstract][Full Text] [Related]
10. Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metapneumovirus F Protein.
Huang J; Chopra P; Liu L; Nagy T; Murray J; Tripp RA; Boons GJ; Mousa JJ
J Virol; 2021 Aug; 95(18):e0059321. PubMed ID: 34160259
[TBL] [Abstract][Full Text] [Related]
11. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
13. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
[TBL] [Abstract][Full Text] [Related]
14. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.
Blais N; Gagné M; Hamuro Y; Rheault P; Boyer M; Steff AM; Baudoux G; Dewar V; Demers J; Ruelle JL; Martin D
J Virol; 2017 Jul; 91(13):. PubMed ID: 28404847
[TBL] [Abstract][Full Text] [Related]
16. A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes.
Swanson KA; Balabanis K; Xie Y; Aggarwal Y; Palomo C; Mas V; Metrick C; Yang H; Shaw CA; Melero JA; Dormitzer PR; Carfi A
J Virol; 2014 Oct; 88(20):11802-10. PubMed ID: 25078705
[TBL] [Abstract][Full Text] [Related]
17. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.
Rigter A; Widjaja I; Versantvoort H; Coenjaerts FE; van Roosmalen M; Leenhouts K; Rottier PJ; Haijema BJ; de Haan CA
PLoS One; 2013; 8(8):e71072. PubMed ID: 23951084
[TBL] [Abstract][Full Text] [Related]
18. Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.
Más V; Rodriguez L; Olmedillas E; Cano O; Palomo C; Terrón MC; Luque D; Melero JA; McLellan JS
PLoS Pathog; 2016 Sep; 12(9):e1005859. PubMed ID: 27611367
[TBL] [Abstract][Full Text] [Related]
19. Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection.
Eichinger KM; Kosanovich JL; Gidwani SV; Zomback A; Lipp MA; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
Front Immunol; 2020; 11():1673. PubMed ID: 32849580
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.
Magro M; Mas V; Chappell K; Vázquez M; Cano O; Luque D; Terrón MC; Melero JA; Palomo C
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3089-94. PubMed ID: 22323598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
